Drug intelligence / Profile preview

PPN4020

Development stage: Preclinical
Lead developer: CereMark Pharma

Overview

PPN4020 is a preclinical-stage drug candidate being developed by CereMark Pharma for the treatment of neurodegenerative diseases. CereMark Pharma is a biotechnology company that focuses on the development of PET imaging agents and therapeutics targeting proteinopathies, such as those involving tau and amyloid-beta aggregates. PPN4020 is part of the company's early-stage pipeline addressing neurodegeneration, although its specific molecular target, mechanism of action, and chemical modality have not been publicly disclosed. The program is currently in the preclinical phase of development.

Targets

Amyloid-beta aggregate (N-terminal epitope)Tau aggregates (Microtubule-associated protein tau (pathological form))

Beyond the preview

Go deeper on PPN4020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPN4020.

Explore the full profile